{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-004644","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.584504+00:00","generated_at":"2026-06-19T00:20:36.172277+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FibroGen reports FY2022 revenue $140.7M, net loss $293.7M; China roxadustat sales up 74%","bullets":["Total revenue $140.7M in 2022 vs $235.3M in 2021 (which included $120M milestone from Astellas).","Net loss $293.7M ($3.14 per share) vs $290.0M prior year; Q4 net loss $66.2M ($0.70 per share).","China roxadustat net product revenue $82.9M in 2022, up 74% YoY; Q4 $23.4M, up 328% YoY.","Cash, equivalents, investments, and AR $442.7M at Dec 31, 2022; funded into 2H 2024.","Five pivotal Phase 3 readouts expected in 2023: pamrevlumab in DMD and IPF, roxadustat in MDS and CIA."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-004644","json":"https://secwatch.observer/filing/0000950170-23-004644.json","markdown":"https://secwatch.observer/filing/0000950170-23-004644.md","text":"https://secwatch.observer/filing/0000950170-23-004644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017023004644/0000950170-23-004644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017023004644/fgen-20230227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T00:20:36.172277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1087b22ee4679ba09474411c66810c245b7f2b05","claim":"KYNTRA BIO, INC. reported the fourth quarter of 2022 results: revenue $34.4 million, net income $66.2 million net loss, EPS $0.70 net loss per basic and diluted share.","evidence_excerpt":"Total revenue for the fourth quarter of 2022 was $34.4 million, as compared to $16.5 million for the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000095017023004644/0000950170-23-004644-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Revenue","value":"$34.4 million"},{"label":"Net income","value":"$66.2 million net loss"},{"label":"EPS","value":"$0.70 net loss per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f5401306e7102b5a71b339e9dbac75992625d1bc","claim":"KYNTRA BIO, INC. reported the full year 2022 results: revenue $140.7 million, net income $293.7 million net loss, EPS $3.14 net loss per basic and diluted share.","evidence_excerpt":"Total revenue for 2022 was $140.7 million as compared to $235.3 million in 2021, which included $120 million of milestone payments from Astellas related to the EU approval of roxadustat.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000095017023004644/0000950170-23-004644-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2022"},{"label":"Revenue","value":"$140.7 million"},{"label":"Net income","value":"$293.7 million net loss"},{"label":"EPS","value":"$3.14 net loss per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}